Djibouti

Reimbursed Care Access

Djibouti maintains strict national controls on psychotropic and narcotic substances under its national drug laws (Loi No. 171/AN/81) and enforces heavy penalties for possession, trafficking, and non-authorized distribution. There is no publicly available, formal medical reimbursement framework or regulatory approval pathway in Djibouti for psychedelic therapies (psilocybin, MDMA, DMT, etc.); access is limited to authorised medical/narcotics channels or approved research under very narrow circumstances, and routine clinical use or insurance reimbursement is not established. Medical anaesthetics such as ketamine appear on WHO essential-medicine lists broadly (used worldwide as an anaesthetic), but national law tightly controls psychotropic substances and penalties for illicit activity are severe in Djibouti.